Trial Profile
A Randomized, Placebo-Controlled, 4-Period, Crossover Study to Assess the Impact of MK-0431 (Sitagliptin) on Incretin Effect and the Role of Specific Incretin Hormones in Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Avexitide
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 08 Oct 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 03 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.